Visceral Obesity Augments Prescription Use: An Analysis of the Cross-sectional Study of NHANES 2011-2018

Overview

Journal PLoS One

Date 2025 Feb 3

PMID 39899523

Authors

Maximino Acevedo-Fernandez

Renata Ochoa Precoma

Leonardo M Porchia

Victor M Posadas

Enrique Torres-Rasgado

M Elba Gonzalez-Mejia

Esther Lopez-Bayghen

Affiliations

Soon will be listed here.

Abstract

Background: Visceral obesity (VATob) increases the risk for many diseases. Central obesity has been associated with an augmented prescription use; however, there is a paucity of research focused on VATob. Here, the aim was to evaluate the association between VATob and prescription use.

Methods: Data was collected from the NHANES dataset (2011-2018). Visceral adipose tissue was measured using dual x-ray absorptiometry, and VATob was defined as ≥100 cm2. Prescription use was collected from the RXQ_RX files and classified according to Vademecum. Association between VATob and prescription use was determined with logistic regression and reported as odds ratios (ORs) with 95% confidence intervals (95%CIs).

Results: 10,952 participants (weighted: 121,090,702) were included, in which 41.8% were VATob and 52.0% of them had ≥1 prescription. Overall, VATob demonstrated an augmented rate of prescription use when compared to non-VATob (52.0% versus 36.7%, p<0.001), specifically with metabolic (4.5-fold increase), cardiovascular (3.9-fold increase), gastrointestinal (2.5-fold increase), and hematopoietic agents (2.3-fold increase). This was associated with increased the risk for overall prescription use (ORoverall = 1.9, 95%CI: 1.7-2.1, p<0.001). Similar results were observed with metabolic and cardiovascular agents. However, when stratified by BMI, normal weight participants (ORmetabolic = 10.4; 95%CI: 6.5-16.6 & ORcardiovascular = 7.0; 95%CI: 4.4-11.1, p<0.001) had a greater risk than the overweight (ORmetabolic = 4.1; 95%CI: 3.0-5.6 & ORcardiovascular = 3.4; 95%CI: 2.5-4.7, p<0.001) or obese participants (ORmetabolic = 3.5; 95%CI: 2.3-5.3 & ORcardiovascular = 3.5; 95%CI: 2.5-4.9, p<0.001).

Conclusion: VATob is associated with augmented prescription use, particularly with cardiovascular and metabolic agents. This association was higher for normal weight participants.

References

Ouchi N, Shibata R, Walsh K . Cardioprotection by adiponectin. Trends Cardiovasc Med. 2006; 16(5):141-6. PMC: 2749293. DOI: 10.1016/j.tcm.2006.03.001. View

Bosello O, Vanzo A . Obesity paradox and aging. Eat Weight Disord. 2019; 26(1):27-35. DOI: 10.1007/s40519-019-00815-4. View

Chooi Y, Ding C, Magkos F . The epidemiology of obesity. Metabolism. 2018; 92:6-10. DOI: 10.1016/j.metabol.2018.09.005. View

Powell-Wiley T, Poirier P, Burke L, Despres J, Gordon-Larsen P, Lavie C . Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021; 143(21):e984-e1010. PMC: 8493650. DOI: 10.1161/CIR.0000000000000973. View

Koenen M, Hill M, Cohen P, Sowers J . Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. 2021; 128(7):951-968. PMC: 8026272. DOI: 10.1161/CIRCRESAHA.121.318093. View

Lira F, Rosa J, Santos R, Venancio D, Carnier J, de Lima Sanches P . Visceral fat decreased by long-term interdisciplinary lifestyle therapy correlated positively with interleukin-6 and tumor necrosis factor-α and negatively with adiponectin levels in obese adolescents. Metabolism. 2010; 60(3):359-65. DOI: 10.1016/j.metabol.2010.02.017. View

Tchernof A, Despres J . Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013; 93(1):359-404. DOI: 10.1152/physrev.00033.2011. View

Harrison S, Dixon P, Jones H, Davies A, Howe L, Davies N . Long-term cost-effectiveness of interventions for obesity: A mendelian randomisation study. PLoS Med. 2021; 18(8):e1003725. PMC: 8437285. DOI: 10.1371/journal.pmed.1003725. View

Hoel R, Giddings Connolly R, Takahashi P . Polypharmacy Management in Older Patients. Mayo Clin Proc. 2021; 96(1):242-256. DOI: 10.1016/j.mayocp.2020.06.012. View

10.

Finelli C, Sommella L, Gioia S, La Sala N, Tarantino G . Should visceral fat be reduced to increase longevity?. Ageing Res Rev. 2013; 12(4):996-1004. DOI: 10.1016/j.arr.2013.05.007. View

11.

Kim J, Choi C, Yum K . Cut-off values of visceral fat area and waist circumference: diagnostic criteria for abdominal obesity in a Korean population. J Korean Med Sci. 2006; 21(6):1048-53. PMC: 2721927. DOI: 10.3346/jkms.2006.21.6.1048. View

12.

Abramowitz M, Sharma D, Folkert V . Hidden Obesity in Dialysis Patients: Clinical Implications. Semin Dial. 2016; 29(5):391-5. PMC: 5014614. DOI: 10.1111/sdi.12516. View

13.

Bray G . Why do we need drugs to treat the patient with obesity?. Obesity (Silver Spring). 2013; 21(5):893-9. DOI: 10.1002/oby.20394. View

14.

Mirza M . Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011; 2011:592404. PMC: 3168494. DOI: 10.5402/2011/592404. View

15.

Padula W, Allen R, Nair K . Determining the cost of obesity and its common comorbidities from a commercial claims database. Clin Obes. 2014; 4(1):53-8. DOI: 10.1111/cob.12041. View

16.

Kalra S, Arora S, Kapoor N . Hidden Obesity. J Pak Med Assoc. 2023; 73(4):937-938. DOI: 10.47391/JPMA.23-28. View

17.

Barrett L, Xing A, Sheffler J, Steidley E, Adam T, Zhang R . Assessing the use of prescription drugs and dietary supplements in obese respondents in the National Health and Nutrition Examination Survey. PLoS One. 2022; 17(6):e0269241. PMC: 9165812. DOI: 10.1371/journal.pone.0269241. View

18.

Domecq J, Prutsky G, Leppin A, Sonbol M, Altayar O, Undavalli C . Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2015; 100(2):363-70. PMC: 5393509. DOI: 10.1210/jc.2014-3421. View

19.

Li H, Shi Q . Drugs and Diseases Interacting with Cigarette Smoking in US Prescription Drug Labelling. Clin Pharmacokinet. 2015; 54(5):493-501. DOI: 10.1007/s40262-015-0246-6. View

20.

Kong M, Xu M, Zhou Y, Geng N, Lin N, Song W . Assessing Visceral Obesity and Abdominal Adipose Tissue Distribution in Healthy Populations Based on Computed Tomography: A Large Multicenter Cross-Sectional Study. Front Nutr. 2022; 9:871697. PMC: 9082940. DOI: 10.3389/fnut.2022.871697. View